9 results about "Uveal tract" patented technology

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

The present invention relates to a sterile ophthalmic composition comprising castor oil and medium-chain triglycerides; to the use of said composition in medicine, in particular for the treatment and / or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, lax eye lid syndrome, thyroid eye disease, pterygium, conjunctival laxity, epithelial damage caused by preservatives, epithelial or anterior chamber damage caused by ocular surgery, corneal limbal cell deficiency, corneal ulceration caused by physical or chemical agents, keratitis, sub-scleritis and uveitis.

A stent implant for treating glaucoma by intraocular fluid drainage from the anterior chamber, for example into the suprachoroidal space. The stent implant is designed to change in shape after being inserted into the eye, during which change the width and / or thickness or the flow cross-section is increased by for example 20%, in another example more than 200%, and in a further example by more than 400%, at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can be largely or completely closed. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. The implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

This utility model discloses a simulated eyeball for ophthalmic surgical demonstrations, comprising a spherical shell formed by splicing two hemispherical shells. The spherical shell includes a scleral simulated shell, an uveal simulated shell, and a retinal simulated shell. At designated locations inside the front end of the spherical shell are simulated structures for the iris, ciliary processes, lens, and suspensory ligaments. The circular hole in the center of the iris simulated structure serves as a simulated pupil. Through its unique three-layer shell design, from the outer scleral simulated shell to the inner uveal and retinal simulated shells, the simulated eyeball accurately reproduces the complex hierarchical structure of the human eye. In particular, the simulated structures within the eyeball, such as the iris, ciliary processes, lens, suspensory ligaments, and pupil, allow trainees to intuitively familiarize themselves with the key internal structures of the eyeball during demonstrations, providing accurate references for surgical procedures and significantly improving the demonstration effect.

The present application provides a kind of in-situ gelling eye drops of ristretin or its salt and its preparation method, the eye drops include ristretin or its salt, gel matrix, pH regulator and water.The application of the eye drops in treating dry eye, lens allergic endophthalmitis, uveitis, macular edema, spring conjunctivitis, atopic keratoconjunctivitis or corneal graft rejection and the like diseases is also involved.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention relates to the field of medicine, namely to ophthalmology, and can be used in the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks. The technical objective is to develop an effective method for the combined treatment of active retinopathy of prematurity type 1 in zone 1, in children with a gestational age of less than 28 weeks, by performing simultaneous transpupillary laser coagulation of the retina only in the nasal quadrants and introducing an angiogenesis inhibitor into the vitreous cavity. The proposed method solves this problem, involving simultaneous transpupillary laser photocoagulation of avascular zones of the retina in the nasal quadrants only and the injection of an angiogenesis inhibitor into the vitreous cavity. This method prevents the development of tractional retinal detachment, which causes blindness and low vision in children, reactivation of active ROP, and postoperative uveitis, which require additional surgical treatment, in 100% of cases.